Cargando…
Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients
Chimeric antigen receptor T cell (CAR-T) therapy has emerged as highly effective in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but only about 40% patients have achieved sustained responses. Here, we conducted a phase II clinical trial testing efficacy and toxicities of CAR-T th...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429371/ https://www.ncbi.nlm.nih.gov/pubmed/36059523 http://dx.doi.org/10.3389/fimmu.2022.969660 |
_version_ | 1784779420491317248 |
---|---|
author | Qu, Changju Zou, Rui Wang, Peng Zhu, Qian Kang, Liqing Ping, Nana Xia, Fan Liu, Hailing Kong, Danqing Yu, Lei Wu, Depei Jin, Zhengming |
author_facet | Qu, Changju Zou, Rui Wang, Peng Zhu, Qian Kang, Liqing Ping, Nana Xia, Fan Liu, Hailing Kong, Danqing Yu, Lei Wu, Depei Jin, Zhengming |
author_sort | Qu, Changju |
collection | PubMed |
description | Chimeric antigen receptor T cell (CAR-T) therapy has emerged as highly effective in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but only about 40% patients have achieved sustained responses. Here, we conducted a phase II clinical trial testing efficacy and toxicities of CAR-T therapy in R/R non-Hodgkin’s lymphoma patients (NCT03196830). Among enrolled patients, 33 R/R DLBCL patients pretreated with DFC (decitabine, fludarabine plus cyclophosphamide) lymphodepletion chemotherapy and infused with tandem CD19-CD22 based CAR-T cells were drawn out for efficacy and toxicities of CAR-T therapy evaluation. With a median follow-up of 10.9(0.6-29.0) months, the best overall response and complete remission (CR) rates were 90.9% and 63.6%, respectively. The median progression-free survival (PFS) was 10.2 months and overall survival (OS) was undefined. The 2-year OS and PFS rates were 54.3% and 47.2%, respectively. No severe grade 4 cytokine release syndrome (CRS) was observed and grade 3 CRS was observed in only 7 patients; 3 patients developed mild immune effect or cell-associated neurotoxic syndrome. All toxicities were transient and reversible and no CAR-T-related mortality. Further subgroup analysis showed that achieving CR was an independent prognostic factor associated with favorable PFS and OS. The 2-year OS and PFS for patients who achieved CR within 3 months (undefined versus undefined P=0.021 and undefined versus undefined P=0.036) or during the follow-up period were significantly longer than those who did not (undefined versus 4.6 months P < 0.0001 and undefined versus 2.0months P<0.001). While severe CRS was also an independent prognostic factor but associated with inferior PFS and OS. The 2-year OS and PFS for patients with grade 3 CRS were significantly shorter than those with grade 0-2 CRS (4.1 months versus undefined P<0.0001 and 1.7 months versus undefined P=0.0002). This study indicated that CD19/CD22 dual-targeted CAR-T therapy under a decitabine-containing lymphodepletion regimen may be a safe, potent effective approach to R/R DLBCL patients. |
format | Online Article Text |
id | pubmed-9429371 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94293712022-09-01 Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients Qu, Changju Zou, Rui Wang, Peng Zhu, Qian Kang, Liqing Ping, Nana Xia, Fan Liu, Hailing Kong, Danqing Yu, Lei Wu, Depei Jin, Zhengming Front Immunol Immunology Chimeric antigen receptor T cell (CAR-T) therapy has emerged as highly effective in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but only about 40% patients have achieved sustained responses. Here, we conducted a phase II clinical trial testing efficacy and toxicities of CAR-T therapy in R/R non-Hodgkin’s lymphoma patients (NCT03196830). Among enrolled patients, 33 R/R DLBCL patients pretreated with DFC (decitabine, fludarabine plus cyclophosphamide) lymphodepletion chemotherapy and infused with tandem CD19-CD22 based CAR-T cells were drawn out for efficacy and toxicities of CAR-T therapy evaluation. With a median follow-up of 10.9(0.6-29.0) months, the best overall response and complete remission (CR) rates were 90.9% and 63.6%, respectively. The median progression-free survival (PFS) was 10.2 months and overall survival (OS) was undefined. The 2-year OS and PFS rates were 54.3% and 47.2%, respectively. No severe grade 4 cytokine release syndrome (CRS) was observed and grade 3 CRS was observed in only 7 patients; 3 patients developed mild immune effect or cell-associated neurotoxic syndrome. All toxicities were transient and reversible and no CAR-T-related mortality. Further subgroup analysis showed that achieving CR was an independent prognostic factor associated with favorable PFS and OS. The 2-year OS and PFS for patients who achieved CR within 3 months (undefined versus undefined P=0.021 and undefined versus undefined P=0.036) or during the follow-up period were significantly longer than those who did not (undefined versus 4.6 months P < 0.0001 and undefined versus 2.0months P<0.001). While severe CRS was also an independent prognostic factor but associated with inferior PFS and OS. The 2-year OS and PFS for patients with grade 3 CRS were significantly shorter than those with grade 0-2 CRS (4.1 months versus undefined P<0.0001 and 1.7 months versus undefined P=0.0002). This study indicated that CD19/CD22 dual-targeted CAR-T therapy under a decitabine-containing lymphodepletion regimen may be a safe, potent effective approach to R/R DLBCL patients. Frontiers Media S.A. 2022-08-17 /pmc/articles/PMC9429371/ /pubmed/36059523 http://dx.doi.org/10.3389/fimmu.2022.969660 Text en Copyright © 2022 Qu, Zou, Wang, Zhu, Kang, Ping, Xia, Liu, Kong, Yu, Wu and Jin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Qu, Changju Zou, Rui Wang, Peng Zhu, Qian Kang, Liqing Ping, Nana Xia, Fan Liu, Hailing Kong, Danqing Yu, Lei Wu, Depei Jin, Zhengming Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients |
title | Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients |
title_full | Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients |
title_fullStr | Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients |
title_full_unstemmed | Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients |
title_short | Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients |
title_sort | decitabine-primed tandem cd19/cd22 car-t therapy in relapsed/refractory diffuse large b-cell lymphoma patients |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429371/ https://www.ncbi.nlm.nih.gov/pubmed/36059523 http://dx.doi.org/10.3389/fimmu.2022.969660 |
work_keys_str_mv | AT quchangju decitabineprimedtandemcd19cd22carttherapyinrelapsedrefractorydiffuselargebcelllymphomapatients AT zourui decitabineprimedtandemcd19cd22carttherapyinrelapsedrefractorydiffuselargebcelllymphomapatients AT wangpeng decitabineprimedtandemcd19cd22carttherapyinrelapsedrefractorydiffuselargebcelllymphomapatients AT zhuqian decitabineprimedtandemcd19cd22carttherapyinrelapsedrefractorydiffuselargebcelllymphomapatients AT kangliqing decitabineprimedtandemcd19cd22carttherapyinrelapsedrefractorydiffuselargebcelllymphomapatients AT pingnana decitabineprimedtandemcd19cd22carttherapyinrelapsedrefractorydiffuselargebcelllymphomapatients AT xiafan decitabineprimedtandemcd19cd22carttherapyinrelapsedrefractorydiffuselargebcelllymphomapatients AT liuhailing decitabineprimedtandemcd19cd22carttherapyinrelapsedrefractorydiffuselargebcelllymphomapatients AT kongdanqing decitabineprimedtandemcd19cd22carttherapyinrelapsedrefractorydiffuselargebcelllymphomapatients AT yulei decitabineprimedtandemcd19cd22carttherapyinrelapsedrefractorydiffuselargebcelllymphomapatients AT wudepei decitabineprimedtandemcd19cd22carttherapyinrelapsedrefractorydiffuselargebcelllymphomapatients AT jinzhengming decitabineprimedtandemcd19cd22carttherapyinrelapsedrefractorydiffuselargebcelllymphomapatients |